Patents by Inventor Yan Kong
Yan Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11928117Abstract: Embodiments of the present invention relate to methods, systems, and computer program products for managing a plurality of live comments. A plurality of live comments is obtained for a video, the plurality of live comments being associated with a plurality of fragments in the video, respectively. A plurality of features are extracted from the plurality of live comments, respectively. A knowledge base is generated for the plurality of live comments based on the plurality of features. With these embodiments, the live comments may be managed in an effective way. Further, the knowledge base may provide answers to a user query.Type: GrantFiled: June 23, 2021Date of Patent: March 12, 2024Assignee: International Business Machines CorporationInventors: Wen Wang, Yi Chen Zhong, Kun Yan Yin, De Shuo Kong, Lu Yu, Yi Ming Wang
-
Publication number: 20230372929Abstract: An integrated testing device and fluid module are disclosed, as well as a method of manufacture. Fluid module contains a reservoir containing a test fluid, and a control vessel. The reservoir discharges test fluid into the control vessel, which discharges the test fluid in a controlled way to a test component.Type: ApplicationFiled: April 24, 2023Publication date: November 23, 2023Inventors: John Kelly, Huw Wallis, Keith Bocchicchio, Shing Yan Kong
-
Patent number: 11633733Abstract: An integrated testing device and fluid module are disclosed, as well as a method of manufacture. Fluid module contains a reservoir containing a test fluid, and a control vessel. The reservoir discharges test fluid into the control vessel, which discharges the test fluid in a controlled way to a test component.Type: GrantFiled: November 21, 2016Date of Patent: April 25, 2023Inventors: John Kelly, Huw Wallis, Keith Bocchicchio, Shing Yan Kong
-
Publication number: 20220154975Abstract: Some embodiments of the present disclosure provide an electric heater, which includes: a housing provided with an air inlet and an air outlet, and the housing internally having an air duct communicated between the air inlet and the air outlet; and a heating member and a convection member both being assembled in the air duct, wherein the heating member being configured for heating the air entering from the air inlet to the air duct during energization, the convection member being configured for blowing a heated air from the air duct to the air outlet for discharging. Herein the air outlet is provided on a bottom end of the housing close to a ground.Type: ApplicationFiled: June 2, 2020Publication date: May 19, 2022Inventors: Bo YU, Yuye LUO, Penge ZHANG, Jian ZHANG, Huaican LIU, Yan KONG, Yesong LI
-
Patent number: 11055839Abstract: The present invention discloses a method for fast judging and optimizing light emitting quality of a light guide plate based on an image processing technology. According to the method, an illuminance diagram of the light guide plate is regarded as a single-color image, illuminance information is converted into a gray level, gray levels of all pixel points are calculated through a gray level histogram, the light outgoing quality of the light guide plate is analyzed according to a discrete degree of the gray levels, positions of the gray levels discrete in distribution in the gray level histogram on the illuminance diagram are found out through programming, a net point filling rate in a corresponding area is directly optimized and is eliminated, and a uniformity degree evaluation formula with a precision P judgment criterion is given. The present invention effectively improves the optimizing efficiency of the light guide plate, and an optimized result is closer to an actual visual effect.Type: GrantFiled: May 17, 2019Date of Patent: July 6, 2021Assignee: JIANGNAN UNIVERSITYInventors: Shumei Gao, Ping Li, Weiying Qian, Jianjun Cao, Yan Kong
-
Publication number: 20190321823Abstract: An integrated testing device and fluid module are disclosed, as well as a method of manufacture. Fluid module contains a reservoir containing a test fluid, and a control vessel. The reservoir discharges test fluid into the control vessel, which discharges the test fluid in a controlled way to a test component.Type: ApplicationFiled: November 21, 2016Publication date: October 24, 2019Inventors: John Kelly, Huw Wallis, Keith Bocchicchio, Shing Yan Kong
-
Publication number: 20190272629Abstract: The present invention discloses a method for fast judging and optimizing light emitting quality of a light guide plate based on an image processing technology. According to the method, an illuminance diagram of the light guide plate is regarded as a single-color image, illuminance information is converted into a gray level, gray levels of all pixel points are calculated through a gray level histogram, the light outgoing quality of the light guide plate is analyzed according to a discrete degree of the gray levels, positions of the gray levels discrete in distribution in the gray level histogram on the illuminance diagram are found out through programming, a net point filling rate in a corresponding area is directly optimized and is eliminated, and a uniformity degree evaluation formula with a precision P judgment criterion is given. The present invention effectively improves the optimizing efficiency of the light guide plate, and an optimized result is closer to an actual visual effect.Type: ApplicationFiled: May 17, 2019Publication date: September 5, 2019Inventors: Weiying QIAN, Shumei GAO, Ping LI, Jianjun CAO, Yan KONG
-
Patent number: 8133726Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: October 6, 2010Date of Patent: March 13, 2012Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 8133972Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: September 28, 2010Date of Patent: March 13, 2012Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 8133728Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: September 21, 2010Date of Patent: March 13, 2012Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 8106153Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: September 28, 2010Date of Patent: January 31, 2012Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 8084256Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: September 21, 2010Date of Patent: December 27, 2011Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 8084253Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: GrantFiled: October 6, 2010Date of Patent: December 27, 2011Assignee: Ortho-McNeil Pharmaceutical Corp.Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Publication number: 20110065187Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: October 6, 2010Publication date: March 17, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Publication number: 20110065186Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: October 6, 2010Publication date: March 17, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Publication number: 20110065180Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: October 6, 2010Publication date: March 17, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Patent number: 7884962Abstract: Apparatus and methods for raster image processing are provided that include a networked computer coupled to a plurality of networked printers, the networked computer adapted to receive a print job, parse the print job into one or more print pieces, load balance the print pieces among the printers based on color use and print speed, and provide a list of the printers that received the print pieces.Type: GrantFiled: June 27, 2005Date of Patent: February 8, 2011Assignee: Electronics for Imaging, Inc.Inventors: Margaret Motamed, Ravi Someshwar, Chew Yan Kong, Ravindranath Gunturu
-
Publication number: 20110027301Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: September 21, 2010Publication date: February 3, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Publication number: 20110021747Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: September 28, 2010Publication date: January 27, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
-
Publication number: 20110020309Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.Type: ApplicationFiled: September 21, 2010Publication date: January 27, 2011Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw